Adding sotatercept (Winrevair) to the treatment regimen for pulmonary arterial hypertension (PAH) in high-risk patients ...

Pulmonary arterial hypertension is caused by narrowing of the blood vessels in the lungs. Learn how it happens, including ...

Discover how Temple Lung Center’s innovative clinical trials provide early access to breakthrough treatments and enhanced ...

Main pulmonary artery diameter is a prognostic indicator in patients with pulmonary arterial hypertension without congenital heart disease.

Pulmonary hypertension is a common consequence of interstitial lung disease (PH-ILD), with the highest rate seen among ...

The interim results of a phase 3 trial of Merck’s pulmonary arterial hypertension (PAH) treatment Winrevair were so ...

Winrevair (sotatercept-csrk), compared to placebo, reduced the risk of all-cause death, lung transplantation, and hospitalization.

Patients taking sotatercept had a 76% relative risk reduction in morbidity and mortality events compared with patients taking ...

Access to a webcast of the presentation will be available on the “Investors” page of Liquidia’s website at https://liquidia.com/investors/events-and-presentations. An archived, recorded version of the ...